Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Editas Medicine, Inc. (EDIT)

Editas Medicine receives approval to start EDIT-401 Phase 1/2 trial in Australia

Neutral Impact 3 of 5 product/contract Written later

Editas Medicine said it received approval to start the Phase 1/2 Strive trial of its experimental gene editing medicine EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia, and submitted the trial for review in New Zealand. The filing states that the company expects to report initial safety and tolerability data in the first quarter of 2027, with topline safety and efficacy data later in 2027, so the program is still at an early clinical stage with no financial results attached.

Key points

  • Trial received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration
  • Trial has been submitted for review in New Zealand; patients in both countries would be eligible to enroll if approved there
  • Initial safety and tolerability data expected in the first quarter of 2027
  • New preclinical data on LDL-C reduction will be presented at the AHA Scientific Sessions on November 8, 2026

The filing

CompanyEditas Medicine, Inc. (EDIT)
Form8-K, current report
Filed with the SECOct 8, 2026, 7:04 AM ET
Accession number0001650664-26-000093

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.